Stephen D Wiviott
Overview
Explore the profile of Stephen D Wiviott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
257
Citations
24611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loesch D, Garg M, Matelska D, Vitsios D, Jiang X, Ritchie S, et al.
Nat Commun
. 2025 Mar;
16(1):2124.
PMID: 40032831
Genomics can provide insight into the etiology of type 2 diabetes and its comorbidities, but assigning functionality to non-coding variants remains challenging. Polygenic scores, which aggregate variant effects, can uncover...
2.
Ruff C, Patel S, Giugliano R, Morrow D, Hug B, Kuder J, et al.
N Engl J Med
. 2025 Jan;
392(4):361-371.
PMID: 39842011
Background: Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct...
3.
Moura F, Kamanu F, Wiviott S, Giugliano R, Udler M, Florez J, et al.
Diabetes Obes Metab
. 2024 Dec;
27(3):1287-1295.
PMID: 39696834
Aims: To evaluate the predictive value of a contemporary type 2 diabetes (T2D) polygenic score (PGS) in detecting incident diabetes across a range of diabetes risk factors. Materials And Methods:...
4.
Small A, Wiviott S
Minerva Cardiol Angiol
. 2024 Nov;
PMID: 39565173
Large-scale clinical outcome trials have demonstrated significant reductions in cardiovascular (CV) and renal outcomes with sodium-glucose cotransporter-2 inhibitors (SGLT2i). These benefits are sustained in patients with a range of left...
5.
Scirica B, Lincoff A, Lingvay I, Bogdanski P, Buscemi S, Colhoun H, et al.
J Am Coll Cardiol
. 2024 Sep;
84(17):1632-1642.
PMID: 39217559
Background: Patients with overweight and obesity are at increased risk of death from multiple causes, including cardiovascular (CV) death, with few therapies proven to reduce the risk. Objectives: This study...
6.
Marston N, Pirruccello J, Melloni G, Kamanu F, Bonaca M, Giugliano R, et al.
Nat Med
. 2024 Aug;
30(9):2641-2647.
PMID: 39107561
Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with an increased risk of cardiovascular (CV) disease in the general population. Currently, it is unclear whether this association is observed...
7.
Moura F, Bellavia A, Berg D, Melloni G, Feinberg M, Leiter L, et al.
Diabetes Obes Metab
. 2024 Jul;
26(10):4441-4449.
PMID: 39056220
Aims: To develop a clinical risk model to identify individuals at higher risk of developing new-onset diabetes and who might benefit more from weight loss pharmacotherapy. Materials And Methods: A...
8.
Apperloo E, Neuen B, Fletcher R, Jongs N, Anker S, Bhatt D, et al.
Lancet Diabetes Endocrinol
. 2024 Jul;
12(8):545-557.
PMID: 38991584
Background: SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are...
9.
Patel S, Kang Y, Im K, Neuen B, Anker S, Bhatt D, et al.
Circulation
. 2024 Apr;
149(23):1789-1801.
PMID: 38583093
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear. Methods: This was...
10.
Zimerman A, Wiviott S, Park J, Murphy S, Ran X, Bramson C, et al.
Eur J Prev Cardiol
. 2024 Mar;
31(10):1216-1223.
PMID: 38484368
Aims: Remnant cholesterol and very low-density lipoprotein cholesterol (VLDL-C) are increasingly recognized risk factors for atherosclerotic disease with few therapeutic options. Angiopoietin-like 3 (ANGPTL3), a key protein in the metabolism...